Clinical trials: Thinning Hair
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Eyelash Hypotrichosis, Alopecia Areata
Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotrichosis (inadequate or not enough…
- Trial name
- NCT01023841
- Testing
- bimatoprost ophthalmic solution 0.03%, Vehicle Sterile Solution
- Where
- 2 sites in United States, Brazil
- Volunteers
- 71 people
- Sponsor
- Allergan
Alopecia, Alopecia, Androgenetic
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia.
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01325337
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 307 people
- Sponsor
- Allergan
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Alopecia, Androgenetic
Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia
Randomized, double-blind, vehicle-controlled, parallel group, multi-dose study of TDM-105795 in male subjects with androgenetic alopecia
- Trial name
- NCT05802173
- Testing
- TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- Technoderma Medicines Inc.
Frontal Fibrosing Alopecia
A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
This purpose of this trial was to investigate the molecular signature of frontal fibrosing alopecia (FFA) and the effect of delgocitinib cream 2% on reversing the FFA disease signature in active lesions.
- Trial name
- NCT05332366
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03137381
- Testing
- CTP-543
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Concert Pharmaceuticals
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Androgenetic Alopecia
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic…
- Trial name
- NCT03742518
- Testing
- Topical SM04554 0.15% solution, Topical SM04554 0.25% solution, Topical vehicle solution
- Where
- 14 sites in Turkey (Türkiye)
- Volunteers
- 675 people
- Sponsor
- Biosplice Therapeutics, Inc.
Chemotherapy-Induced Alopecia
Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Chemotherapy-Induced Alopecia
The goal of this clinical trial is to learn if Compound 31543 (topical calcitriol) for treatment of hair-loss in patients with a diagnosis of breast cancer, gynecologic cancer or sarcomas receiving a taxane-based chemotherapy is…
- Trial name
- NCT01588522
- Testing
- Compound 31543 Calcitriol 5 μg/mL, Compound 31543 Calcitriol 10 μg/mL, Compound 31543 Calcitriol 20 μg/mL
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- BPGbio
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 9 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT00981461
- Testing
- HairMax LaserComb, Control Device
- Where
- 5 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Alopecia Universalis (AU), Alopecia Totalis (AT)
Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)
The primary objective is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-50002 Topical Solution compared to vehicle in subjects with AU and AT.
- Trial name
- NCT03315689
- Testing
- Vehicle, ATI-50002
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aclaris Therapeutics, Inc.
Alopecia, Baldness
Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss
This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss.
- Trial name
- NCT01325350
- Testing
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Where
- 2 sites in United States, Germany
- Volunteers
- 306 people
- Sponsor
- Allergan
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA2 (NCT04797650)
- Testing
- CTP-543
- Where
- 63 sites in United States, Canada and 5 more
- Volunteers
- 517 people
- Sponsor
- Concert Pharmaceuticals
Alopecia, Alopecia, Androgenetic
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT01904721
- Testing
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Allergan
Androgenetic Alopecia
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgenetic alopecia.
- Trial name
- NCT01231607
- Testing
- 1mg Finasteride active, 0.02mg dutasteride, 0.1mg dutasteride
- Where
- 39 sites in Argentina, Chile and 7 more
- Volunteers
- 917 people
- Sponsor
- GlaxoSmithKline
Hair Thinning
Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair
The Nutra Harmony "Biotin, Collagen \& Keratin Beauty Complex" is an oral food/dietary supplement specifically designed to promote hair growth for people suffering from temporary thinning hair.
- Trial name
- NCT06605768
- Testing
- Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.
- Where
- Ukraine
- Volunteers
- 80 people
- Sponsor
- Nutra Harmony LLC